- Home
- WAI vs NRXP Comparison
WAI vs NRXP Comparison
Compare WAI & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WAI
- NRXP
- Stock Information
- Founded
- WAI 2018
- NRXP 2015
- Country
- WAI China
- NRXP United States
- Employees
- WAI N/A
- NRXP N/A
- Industry
- WAI
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- WAI
- NRXP Health Care
- Exchange
- WAI NYSE
- NRXP Nasdaq
- Market Cap
- WAI 33.5M
- NRXP 32.6M
- IPO Year
- WAI 2023
- NRXP N/A
- Fundamental
- Price
- WAI $0.48
- NRXP $3.34
- Analyst Decision
- WAI
- NRXP Strong Buy
- Analyst Count
- WAI 0
- NRXP 4
- Target Price
- WAI N/A
- NRXP $28.50
- AVG Volume (30 Days)
- WAI 1.7M
- NRXP 240.0K
- Earning Date
- WAI 08-24-2025
- NRXP 08-13-2025
- Dividend Yield
- WAI N/A
- NRXP N/A
- EPS Growth
- WAI N/A
- NRXP N/A
- EPS
- WAI N/A
- NRXP N/A
- Revenue
- WAI $3,750,352.00
- NRXP N/A
- Revenue This Year
- WAI N/A
- NRXP N/A
- Revenue Next Year
- WAI N/A
- NRXP N/A
- P/E Ratio
- WAI N/A
- NRXP N/A
- Revenue Growth
- WAI N/A
- NRXP N/A
- 52 Week Low
- WAI $0.46
- NRXP $1.10
- 52 Week High
- WAI $20.00
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- WAI N/A
- NRXP 60.08
- Support Level
- WAI N/A
- NRXP $2.90
- Resistance Level
- WAI N/A
- NRXP $3.53
- Average True Range (ATR)
- WAI 0.00
- NRXP 0.19
- MACD
- WAI 0.00
- NRXP -0.03
- Stochastic Oscillator
- WAI 0.00
- NRXP 84.13
About WAI TOP KINGWIN LTD
Top KingWin Ltd operates as a corporate business training and consulting company, providing personal and management training and financial consulting services. It provides some essential business services in China to young and emerging companies, including corporate business training services, which mainly focus on knowledge and new perspectives on the capital markets; corporate consulting services, which mainly focus on various aspects of fundraising; and advisory and transaction services. Its main clients are entrepreneurs and executives in China's small and medium enterprises (SMEs).
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.